Dopamine and serotonin interactions in the prefrontal cortex: Insights on antipsychotic drugs and their mechanism of action

Pharmacopsychiatry

Volumn 40, Issue SUPPL. 1, 2007, Pages

  Di Pietro, N C ^a,b   Seamans, J K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID; AMISULPRIDE; ARIPIPRAZOLE; BICUCULLINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; EGLUMETAD; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; PALIPERIDONE; PICROTOXIN; QUETIAPINE; QUINPIROLE; RACLOPRIDE; REPINOTAN; SEROTONIN; SEROTONIN 2A RECEPTOR; VOLINANSERIN;

BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISSOCIATION; DOPAMINE RELEASE; DRUG ANTAGONISM; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; ELECTROENCEPHALOGRAM; HUMAN; IN VITRO STUDY; MONOTHERAPY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA; SEROTONIN RELEASE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMANS; PREFRONTAL CORTEX; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN;

EID: 37549046758     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992133     Document Type: Conference Paper

References (103)

1. Aghajanian GK, Marek GJ. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997; 36 (4-5): 589-599
2. Aghajanian GK, Marek GJ. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999; 825 (1-2): 161-171
3. Araneda R, Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991; 40 (2): 399-412
4. Arvanov VL, Liang X, Magro P, Roberts R, Wang RY. A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 1999; 11 (8): 2917-2934
5. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005; 315 (1): 265-272
6. Auclair A, Blanc G, Glowinski J, Tassin JP. Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors. J Neurochem 2004; 91 (2): 318-326
7. Beique JC, Chapin-Penick EM, Mladenovic L, Andrade R. Serotonergic facilitation of synaptic activity in the developing rat prefrontal cortex. J Physiol 2004; 556 (Pt 3): 739-754
8. Beique JC, Imad M, Mladenovic L, Gingrich JA, Andrade R. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci USA 2007; 104 (23): 9870-9875
9. Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005; 95 (6): 1597-1607
10. Burnet PWJ, Chen CPL-H, MacGowan S, Franklin M, Harrison PJ. The effects of clozapine and haloperidol on serotonin -1A, -2A, and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 1996; 73: 531-540
11. Cai X, Flores-Hernandez J, Feng J, Yan Z. Activity-dependent bidirectional regulation of GABA(A) receptor channels by the 5-HT(4) receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. J Physiol 2002a; 540 (Pt 3): 743-759
12. Cai X, Gu Z, Zhong P, Ren Y, Yan Z. Serotonin 5-HT1A receptors regulate AMPA receptor channels through inhibiting Ca2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. J Biol Chem 2002b; 277 (39): 36553-36562
13. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 Suppl 1:S10-S14
14. Carr DB, Cooper DC, Ulrich SL, Spruston N, Surmeier DJ. Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. J Neurosci 2002; 22 (16): 6846-6855
15. Chen G, Greengard P, Yan Z. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci USA 2004; 101 (8): 2596-2600
16. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003; 1003: 318-327
17. Devoto P, Flore G, Pani L, Gessa GL. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 2001; 6: 657-664
18. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005; 25 (47): 10831-10843
19. Durstewitz D. A few important points about dopamine's role in neural network dynamics. Pharmacopsychiatry 2006; 39 Suppl 1: S72-S75
20. Durstewitz D, Seamans JK. The computational role of dopamine D1 receptors in working memory. Neural Netw 2002; 15: 561-572
21. Fischette CT, Nock B, Renner K. Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res 1987; 421 (1-2): 263-279
22. Garris PA, Ciolkowski EL, Pastore P, RM. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 1994; 14: 6084-6093
23. Garris PA, Collins LB, Jones SR, Wightman RM. Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J Neurochem 1993; 61: 637-647
24. Garris PA, Wightman RM. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 1994; 14: 442-450
25. Gellman RL, Aghajanian GK. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res 1993; 600 (1): 63-73
26. Gobert A, Millan MJ. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 1999; 38 (2): 315-317
27. Goldman-Rakic PS, Muly 3rd EC, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Rev 2000; 31 (2-3): 295-301
28. Gonzalez-Burgos G, Kroener S, Seamans JK, Lewis DA, Barrionuevo G. Dopaminergic modulation of short-term synaptic plasticity in fast-spiking interneurons of primate dorsolateral prefrontal cortex. J Neurophysiol 2005; 94 (6): 4168-4177
29. Gonzalez-Islas C, Hablitz JJ. Dopamine enhances EPSCs in layer II-III pyramidal neurons in rat prefrontal cortex. J Neurosci 2003; 23: 867-875
30. Gorelova N, Seamans JK, Yang CR. Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 2002; 88: 3150-3166
31. Gorelova NA, Yang CR. Dopamine D1/D5 receptor activation modulates a persistent sodium current in rat prefrontal cortical neurons in vitro. J Neurophysiol 2000; 84: 75-87
32. Gu Z, Jiang Q, Yan Z. RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 2007; 71 (4): 1030-1039
33. Gulledge AT, Joffe DB. Multiple effects of dopamine on layer V pyramidal cell excitability in rat prefrontal cortex. J Neurophysiol 2001; 86: 586-595
34. Henze DA, Gonzalez-Burgos GR, Urban NN, Lewis DA, Barrionuevo G. Dopamine increases excitability of pyramidal neurons in primate prefrontal cortex. J Neurophysiol 2000; 84: 2799-2809
35. Hernandez L, Hoebel BG. Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats. Pharmacol Biochem Behav 1995; 52: 581-589
36. Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998; 779: 214-225
37. Huang YY, Kandel ER. D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci USA 1995; 92: 2446-2450
38. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76(5): 1521-1531
39. Ichikawa J, Kuroki T, Dai J, Meltzer HY. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 1998; 351 (2): 163-171
40. Iyer RN, Bradberry CW. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 1996; 277 (1): 40-47
41. Izaki Y, Hori K, Nomura, M. Dopamine and acetylcholine elevation on lever-press acquisition in rat prefrontal cortex. Neurosci Lett 1998; 258: 33-36
42. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the primate cerbral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 1998; 95: 735-740
43. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20 (3): 201-225
44. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (7): 1081-1090
45. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158 (3): 360-369
46. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, MacEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164 (7): 1061-1071
47. Krystal JH, Belger AD, Douza C, Anand A, Chamey DS, Aghajanian GK et al. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 1999; 22: A143-A157
48. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288 (2): 774-781
49. Lambe EK, Aghajanian GK. The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci 2001; 21 (24): 9955-9963
50. Lambe EK, Goldman-Rakic PS, Aghajanian GK. Serotonin induces EPSCs preferentially in layer V pyramidal neurons of the frontal cortex in the rat. Cereb Cortex 2000; 10 (10): 974-980
51. Lucas G, Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 2000; 74 (2): 693-701
52. Marek GJ, Aghajanian GK. 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by μ-opiate receptor activation. Neuroscience 1998; 86 (2): 485-497
53. Marek GJ, Aghajanian GK. 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 1999; 367 (2-3): 197-206
54. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 2001; 105 (2): 379-392
55. Matsubara S, Meltzer HY. Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 1989; 45: 1397-1406
56. Matsumoto M, Togashi H, Mori K, Ueno K, Miyamoto A, Yoshioka M. Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur J Pharmacol 1999; 383 (1): 39-48
57. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacol (Berl) 1989; 99 Suppl 1: S18-S27
58. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (7): 1159-1172
59. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000; 295 (3): 853-861
60. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005; 10: 79-104
61. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17 (8): 2921-2927
62. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (4): 659-665
63. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22: 389-395
64. Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101 (2): 131-181
65. O'Dell SJ, Hoste GJ La, Widmark CB, Potkin SG, Marshall JF. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 1990; 6: 146-153
66. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995; 13 (4): 335-345
67. Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain II. Serotonin-2 receptors. Brain Res 1985; 346 (2): 231-249
68. Pehek EA, MacFarlane HG, Maguschak K, Price B, Pluto CP. M100.907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 2001; 888 (1): 51-59
69. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress-and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006; 31 (2): 265-277
70. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000; 48 (3): 229-237
71. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27 (11): 2979-2986
72. Schmidt CJ, Fadayel GM. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995; 273 (3): 273-279
73. Seeman P. The absolute density of neurotransmitter receptors in the brain. Example for dopamine receptors. J Pharmacol Methods 1987; 17 (4): 347-360
74. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47 (1): 27-38
75. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005; 162 (10): 1984-1985
76. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987; 1 (1): 5-15
77. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, MacKnight GS et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006; 60 (4): 319-346
78. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156 (6): 876-884
79. Seamans JK, Durstewitz D, Christie B, Stevens CF, Sejnowski TJ. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 2001a; 98: 301-306
80. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001b; 21: 3628-3638
81. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74(1): 1-58
82. Sesack SR, Hawrylak VA, Guido MA, Levey AI. Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol 1998; 42: 171-174
83. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 1992; 320 (2): 145-160
84. Sheldon PW, Aghajanian GK. Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex: evidence for the involvement of a 5-HT2-activated interneuron. Brain Res 1990; 506 (1): 62-69
85. Sheldon PW, Aghajanian GK. Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: evidence for mediation by 5-HT1C receptors in pyramidal cells and 5-HT2 receptors in interneurons. Synapse 1991; 9 (3): 208-218
86. Shoblock JR, Maisonneuve IM, Click SD. Differences between D-methamphetamine and D-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology 2003; 170: 150-156
87. Tanaka E, North RA. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 1993; 69 (5): 1749-1757
88. Trantham-Davidson H, Kroner S, Seamans JK. Dopamine modulation of prefrontal cortex interneurons occurs independently of DARPP-32. Cereb Cortex 2007, in press
89. Trantham-Davidson H, Neely LC, Lavin A, Seamans JK. Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 2004; 24 (47): 10652-10659
90. Tseng KY, O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 2004; 24 (22): 5131-5139
91. Wang XJ. Toward a prefrontal microcircuit model for cognitive deficits in schizophrenia. Pharmacopsychiatry 2006; 39 Suppl 1: S80-S87
92. Westerink BH, Kawahara Y, Boer P De, Geels C, Vries JB De, Wikstrom HV et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001; 412 (2): 127-138
93. Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997; 27: 32-79
94. Wilmot CA, Szczepanik AM. Effects of acute and chronic treatment with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 1989; 487: 288-298
95. Winterer G. Cortical microcircuits in schizophrenia - the dopamine hypothesis revisited. Pharmacopsychiatry 2006; 39 Suppl 1: S68-S71
96. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004; 27 (11): 683-690
97. 2A) receptors in the rat brain. Brain Res Bull 2000; 51: 499-505
98. Yang CR, Seamans JS. Dopamine D1 receptor actions in layer V-VI rat prefrontal cortex neurons in vitro: modulation of dendritic-somatic signal integration. J Neurosci 1996; 16: 1922-1935
99. Yuen EY, Jiang Q, Chen P, Gu Z, Feng J, Yan Z. Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J Neurosci 2005; 25 (23): 5488-5501
100. Zahorodna A, Bobula B, Grzegorzewska M, Tokarski K, Hess G. The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT(1A), 5-HT(2) and 5-HT(4) receptors in rat frontal cortex. J Physiol Pharmacol 2004; 55 (2): 371-379
101. Zheng P, Zhang XX, Bunney BS, Shi WX. Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience 1999; 91 (2): 527-535
102. Zhong P, Yan Z. Chronic antidepressant treatment alters serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons. Neuroscience 2004; 129 (1): 65-73
103. Zhou FM, Hablitz JJ. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol 1999; 82 (6): 2989-2999